US Patent
US11975017 — Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
Formulation · Assigned to Gilead Sciences Inc · Expires 2038-07-10 · 12y remaining
Vulnerability score
38/100
Strong — defensible against typical IPR challenges
What this patent protects
This patent protects a composition containing Compound 1, cyclodextrin, and optional pH adjusting agents for treating viral infections.
USPTO Abstract
The present disclosure provides a composition comprising Compound 1, or a pharmaceutically acceptable salt thereof, cyclodextrin, and, optionally, pH adjusting agents.
Drugs covered by this patent
- Veklury (remdesivir) · Gilead Sciences
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.